Blog

  • ECB Warns Higher Gas Prices Could Feed Into Eurozone Inflation More Quickly

    ECB Warns Higher Gas Prices Could Feed Into Eurozone Inflation More Quickly

    Rising natural gas prices could affect eurozone consumer inflation more rapidly than in the past, although their impact on electricity prices may be reduced by the growing contribution of renewable energy, according to a European Central Bank (ECB) Economic Bulletin.

    European wholesale natural gas prices have increased by more than 140% compared with a year earlier. The conflict involving Iran has constrained global supplies, while low European gas inventories have increased the risk of further price rises.

    The ECB said changes in European gas markets following Russia’s invasion of Ukraine in 2022 have accelerated the transmission of wholesale price movements to household energy bills.

    Greater price flexibility and increased use of shorter-term contracts mean retail gas prices can respond more quickly to changes in wholesale markets.

    Gas Price Changes Reach Consumers Faster

    A survey conducted by European Union central banks found that wholesale gas price changes are now reflected in consumer gas inflation within one to three months in more than half of eurozone countries.

    In approximately one-tenth of countries, the transmission takes four to six months. In around one-third, the process takes between seven and 12 months.

    The proportion of countries reporting a slower transmission period of 13 to 24 months has declined substantially compared with 2022.

    The ECB stated: “Specifically, the share of countries reporting a slow transfer within a period of 13 to 24 months has fallen from around 40% to around 5% by 2022,”

    The findings indicate that wholesale gas price increases could influence household energy costs and headline inflation sooner than during previous energy market disruptions.

    Implications for Inflation and Interest Rates

    The ECB’s assessment comes as eurozone inflation is already above 3%, exceeding the central bank’s 2% target.

    Some economists expect inflation to reach 4% by the end of the year, potentially adding pressure on the ECB to consider further interest rate increases following its actions over the preceding two months.

    However, the report distinguishes between the impact of higher gas prices on household gas bills and their effect on electricity costs.

    The expansion of renewable electricity generation has reduced the role of natural gas in determining electricity production costs, limiting the extent to which wholesale gas price movements feed through to electricity inflation.

    “These developments suggest that changes in wholesale gas prices may be reflected in HICP gas inflation more rapidly than in the past, but to a lesser extent in HICP electricity inflation,” the ECB said, referring to the Harmonised Index of Consumer Prices.

    The analysis suggests that the inflationary consequences of the latest gas price increases will depend partly on national retail pricing arrangements and the changing composition of Europe’s electricity supply.

  • MedPal AI: From Zero to £35m Annualised Revenue as Growth Accelerates

    MedPal AI: From Zero to £35m Annualised Revenue as Growth Accelerates

    MedPal AI is scaling at remarkable speed, with September trading showing further acceleration and the Group now running at more than £35 million of annualised revenue just eleven months after starting from zero.

    The latest trading update from MedPal AI plc (LSE:MPAL) provides another clear indication of the pace at which the AI-native digital health and pharmacy group is building its business.

    The headline number is striking: based on trading between 1 and 19 September, MedPal’s annualised revenue run rate has climbed to more than £35 million, up from approximately £28 million in August and £8.6 million in July. The company is careful to point out that these are annualised figures based on monthly trading rather than forecasts.

    For investors, however, the direction of travel is difficult to ignore.

    New Health continues to drive the acceleration

    The key growth engine is New Health, MedPal’s dedicated GLP-1 weight-management clinic.

    New Health generated more than £1.5 million of revenue in the first 19 days of September, from more than 12,000 orders. That represents a daily trading rate approximately 35% higher than August, while August itself delivered revenue growth of more than 800% compared with July.

    The customer numbers are expanding just as quickly.

    New Health has now acquired more than 25,000 customers since marketing began in July, compared with more than 16,000 reported just two weeks earlier.

    That rapid customer acquisition is already translating into significant operational scale.

    On 15 September, New Health recorded its biggest trading day to date, dispensing 2,000 orders and generating approximately £300,000 of revenue in a single day.

    For a business that only began trading in June, the progression is significant.

    The repeat-order opportunity

    Perhaps one of the more interesting elements of the update is what could happen as the rapidly acquired customer base matures.

    MedPal says 27% of first-time customers have already placed a second order, despite the majority of New Health customers having joined during the second half of August or in September and therefore still being on their first month’s medication.

    That gives the company an increasingly valuable second layer of potential growth: new customer acquisition alongside repeat purchasing from the existing customer base.

    Importantly, repeat orders do not carry the same customer acquisition cost as the initial sale, meaning the company expects margins to widen as the customer base matures.

    This is potentially an important part of the investment story as MedPal moves from rapid customer acquisition towards building a recurring customer relationship.

    £5m raise to fund the growth

    MedPal has also announced a £5 million placing at 5p per share, predominantly supported by existing shareholders alongside institutional and other investors.

    The key point is where that capital is going.

    Approximately £4 million of the £4.7 million net proceeds will be used to fund medication stock and working capital, allowing the Group to purchase medication ahead of receiving NHS payments, supplier rebates and VAT reclaims.

    A further approximately £700,000 will be invested in expanding the GLP-1 pick-and-pack operation at the company’s Sarus Court facility.

    That investment is expected to increase capacity to 14,000 orders per day, equivalent to approximately £2 million of orders per day, with the expanded line expected to be operational by the end of October.

    In other words, MedPal is putting capital behind infrastructure designed to accommodate further growth.

    A business beginning to scale

    There is another potentially important development in the background.

    MedPal has opened discussions with UK clearing banks regarding a working-capital facility secured against its receivables. The discussions remain at an early stage, but if successful, the company expects such a facility could reduce the need for further equity to fund its working-capital cycle as the business expands.

    That would represent an important evolution for a company currently growing so rapidly that working capital itself has become a constraint.

    CEO and founder Jason Drummond summed up the situation by saying that growth at this pace needs to be funded and that the placing allows MedPal to accelerate rather than pace its growth according to available cash.

    The bigger picture

    MedPal’s story is increasingly about more than a single fast-growing digital pharmacy.

    The Group’s annualised revenue now comprises approximately £29 million from New Health, £5.6 million from NHS prescriptions and £0.8 million from eMARx, according to the latest update.

    That combination gives MedPal exposure to digital pharmacy, healthcare services, NHS prescriptions, GLP-1 weight management and its developing health technology platform.

    The numbers also demonstrate just how quickly the business has moved.

    From zero to an annualised revenue run rate above £35 million in eleven months is a dramatic rate of expansion. The next question for investors is whether MedPal can convert that rapid top-line growth into a progressively more profitable and cash-generative business as customer numbers mature, repeat orders increase and operational capacity expands.

    For now, the latest update suggests that MedPal is still accelerating rather than slowing down.

    With more than 25,000 New Health customers, record daily order volumes, early evidence of repeat purchasing, a £5 million injection of growth capital and capacity expansion underway, the company enters the final quarter of 2026 with its operating platform being built around a business that is scaling at pace.

    For investors watching the rapidly evolving UK digital-health market, MedPal’s latest figures put the company firmly on the radar.

  • Market Open: Anglo Asian Mining, Iofina Results

    Market Open: Anglo Asian Mining, Iofina Results

    FTSE 100 and European stocks rise as Anglo Asian Mining and Iofina report results. Brent crude falls amid Middle East diplomatic developments.

    Market Overview

    The FTSE 100 opened 0.47 per cent higher at 10,709.21, as investors assessed developments in Middle East diplomacy and easing oil prices. European equities also advanced, with the Euronext 100 gaining 0.72 per cent and Germany’s DAX rising 0.68 per cent. In the US, the Nasdaq closed higher at 26,522.55, while the S&P 500 advanced to 7,650.50.

    Commodity markets showed mixed movements, with copper advancing while gold, Brent crude and natural gas declined. Oil prices remained sensitive to Middle East developments, including diplomatic efforts involving Iran and reports of a Houthi attack on Saudi Arabia. Against sterling, the US dollar, Swiss franc, euro and Australian dollar strengthened, while the Japanese yen weakened. Bitcoin also moved higher.


    Market Numbers

    FTSE 100: Up (+0.47%), 10,709.21

    Euronext 100: Up (+0.72%), 1,894.71

    DAX: Up (+0.68%), 25,476.04

    NASDAQ: Up, 26,522.55

    S&P 500: Up, 7,650.50


    In the Headlines

    Record Copper Production – Anglo Asian Mining (LSE:AAZ)
    Anglo Asian Mining reported first-half revenue of $141.2 million as copper production reached a record 8,840 tonnes. The results highlight the mining group’s transition towards copper-focused operations and increased production capacity.

    Earnings Growth – Iofina (LSE:IOF)
    Iodine producer Iofina reported a 7 per cent increase in first-half revenue to $31.3 million, while adjusted EBITDA more than doubled. The results indicate improved operating profitability alongside revenue growth.


    Currencies (vs GBP)

    USD: Up (+0.09%), $1.3378

    CHF: Unchanged (0.00%), Fr.1.1014

    EUR: Up (+0.07%), €1.1657

    JPY: Down (-0.04%), ¥210.2995

    AUD: Up (+0.16%), $1.8771

    Bitcoin (BTC/GBP): Up, £60,948.57


    Commodities

    Copper: Up

    Gold: Down

    Brent Crude: Down

    Natural Gas: Down

  • FTSE 100 Rises 0.43% as Oil Prices Decline Amid US-Iran Diplomatic Developments

    FTSE 100 Rises 0.43% as Oil Prices Decline Amid US-Iran Diplomatic Developments

    The FTSE 100 rose 0.43% on Monday as oil prices declined amid developments surrounding potential diplomatic efforts to de-escalate the conflict between the United States and Iran.

    As of 07:15 GMT, Germany’s DAX had gained 0.72%, while France’s CAC 40 advanced 0.70%. Sterling fell 0.16% against the US dollar to $1.3373.

    Brent crude futures for November delivery declined 2% to $101.77 a barrel, while November West Texas Intermediate futures fell 2.13% to $94.03.

    The movements came as investors assessed developments involving Iran and the United States, including conflicting reports on shipping activity through the Strait of Hormuz.

    Iran’s Revolutionary Guards spokesperson Hossein Mohebbi said the United States “has been defeated in this war” and had failed to reopen the Strait of Hormuz, according to comments reported by local media.

    Mohebbi also warned that further US military action would prompt Iran to deploy additional weapons capabilities.

    Separately, Iranian lawmakers submitted legislation proposing withdrawal from the Nuclear Non-Proliferation Treaty, according to state-owned Press TV.

    US envoy to the United Nations Mike Waltz indicated on social media platform X that negotiations remained possible if Iran returned to discussions in good faith.

    Shipping data continued to present differing assessments of activity through the Strait of Hormuz.

    Reuters counted 12 commodity vessels transiting the waterway over the weekend, compared with 35 during the preceding weekend.

    The UK Maritime Trade Operations organisation reported independent tracking figures showing single-digit vessel movements in both directions, while figures linked to the US Navy indicated more than 30 transits per day.

    Jefferies strategist Mohit Kumar identified Thursday’s scheduled meeting between US President Donald Trump and Chinese President Xi Jinping as an event for investors to monitor.

    Kumar also suggested that early October could provide an opportunity for an interim arrangement between Washington and Tehran, although no agreement has been announced.

    Elsewhere in Europe, investors continued to assess fiscal and political developments.

    The Euro Stoxx index declined 1.4% on Friday, while French 10-year government bond yields increased by 14 basis points amid concerns about the country’s budget deficit, according to Jefferies.

    The investment bank also noted that German Chancellor Friedrich Merz’s party had recorded its worst result in a state election.

    In commodities, gold prices declined alongside oil. December gold futures fell 0.76% to $4,390.65 an ounce, while spot gold decreased 0.57% to $4,351.36.

    UK Corporate News

    Elixirr International (LSE:ELIX) reported a 25% increase in first-half revenue to £89.0 million, supported by growth in artificial intelligence-related services.

    AI-related revenue rose 185% to £8.1 million, while adjusted EBITDA increased 29% to £27.6 million.

    The consultancy maintained its outlook for full-year revenue and adjusted EBITDA, which it expects to be broadly in line with company-compiled market expectations.

  • JD Sports Enters Mexico Through Franchise Partnership With Grupo Axo

    JD Sports Enters Mexico Through Franchise Partnership With Grupo Axo

    JD Sports (LSE:JD) has announced its entry into the Mexican market through a long-term franchise partnership with fashion retailer Grupo Axo.

    Under the agreement, Grupo Axo will operate JD-branded stores and e-commerce activities in Mexico using the British sportswear retailer’s brand and intellectual property.

    The partnership will incorporate JD Sports’ own-brand and exclusive product ranges across footwear, clothing and accessories.

    Grupo Axo will operate more than 140 JD premises in Mexico through its existing sneaker retail network. The partners also plan to expand the store portfolio at selected locations over time.

    The agreement establishes a franchise-based operating structure for JD Sports in Mexico, with Grupo Axo responsible for local retail and online operations.

    JD Sports Chief Executive Régis Schultz commented on the company’s plans for the market.

    “We see a significant opportunity to lead the category in Mexico,” said CEO Régis Schultz.

    The partnership represents an expansion of JD Sports’ international retail operations through a local franchise partner. The company has not disclosed financial terms, investment commitments or a timetable for additional store openings.

  • Elixirr H1 Revenue Rises 25% to £89 Million as AI-Related Revenue Reaches £8.1 Million

    Elixirr H1 Revenue Rises 25% to £89 Million as AI-Related Revenue Reaches £8.1 Million

    Elixirr International (LSE:ELIX) reported a 25% increase in revenue to £89.0 million for the first half of 2026, supported by growth in artificial intelligence-related services and its broader consulting operations.

    The consultancy said AI-related revenue rose 185% to £8.1 million from £2.8 million in the corresponding period last year. Organic revenue growth at constant currency was 5%.

    Adjusted EBITDA increased 29% to £27.6 million, while the adjusted EBITDA margin expanded to 31.0% from 30.0% a year earlier.

    Adjusted profit before tax rose 25% to £25.1 million, and adjusted diluted earnings per share increased 18% to 34.2 pence.

    The company reported an increase in revenue from its existing client relationships, with 35 clients generating more than £1 million each during the period, compared with 31 a year earlier.

    Cross-selling revenue increased 27% to £19 million, reflecting additional services provided to existing customers.

    Chief Executive Stephen Newton said businesses are increasingly moving from evaluating the potential applications of artificial intelligence towards implementing the technology within their operations.

    He also highlighted the company’s investment in consulting, AI, data and technology capabilities over the past six years.

    “The scale of the opportunity ahead is significant. Industry research estimates that agentic AI alone could create up to $200 billion of new demand for technology services over the next five years. We have spent the last six years deliberately building our consulting, AI, data and technology capabilities to benefit from this shift,” he said.

    The industry demand estimate cited by Newton relates specifically to agentic AI technology services and represents a forecast rather than contracted business for Elixirr.

    The company continues to develop its AI-related consulting and technology services alongside its existing advisory operations.

    Looking ahead, Elixirr expects total adjusted EBITDA for FY 26 will be in line with market expectations and revenue will be broadly in line.

    The outlook follows first-half growth across revenue, adjusted earnings and AI-related services, with the company maintaining its existing full-year financial expectations.

  • Syncona Shares Rise 7.4% After Beacon Therapeutics Gene Therapy Trial Meets Primary Endpoint

    Syncona Shares Rise 7.4% After Beacon Therapeutics Gene Therapy Trial Meets Primary Endpoint

    Syncona (LSE:SYNC) shares rose 7.4% after its portfolio company Beacon Therapeutics announced that its pivotal Phase II/III VISTA trial of laru-zova, a gene therapy for X-linked retinitis pigmentosa (XLRP), met its primary endpoint with statistical significance at 12 months.

    The announcement was published through a Regulatory News Service filing and identified as containing inside information. Syncona described the results as an important development for Beacon, in which it holds a 38.4% ownership stake.

    The VISTA study evaluated 85 male patients aged between 12 and 48 across two dosing cohorts, assessing improvements in low-luminance visual acuity.

    The high-dose group achieved a responder rate of 31.0%, while the low-dose group recorded a responder rate of 24.1%. Both results were statistically significant against the trial’s primary endpoint, which had been endorsed by the US Food and Drug Administration (FDA).

    According to Beacon, VISTA is the first pivotal trial in XLRP to meet its primary endpoint.

    Following the results, Beacon plans to initiate pre-submission discussions with regulatory authorities internationally. The company intends to begin a rolling Biologics License Application (BLA) submission later in 2026.

    Additional clinical data are scheduled to be presented at the American Academy of Ophthalmology Annual Meeting on 10 October.

    Syncona’s 38.4% holding in Beacon was valued at £183.4 million as of 30 June 2026, before the announcement of the VISTA results.

    The clinical outcome represents a development for one of Syncona’s portfolio investments, although any subsequent change in its carrying value has not been quantified in the information provided.

    In market trading, Syncona shares advanced 7.4% and approached a 52-week high of 120.2 pence during the session. The stock’s 52-week low stood at 86.9 pence.

    The increase occurred during a session in which the broader UK equity market declined, with both the FTSE 100 and FTSE 250 finishing lower and financial stocks contributing to the losses.

    Syncona is a life sciences investment company with a portfolio that includes Beacon Therapeutics. The latest clinical results provide additional data on laru-zova as Beacon prepares for regulatory discussions and its planned BLA submission.

    The next scheduled developments include the presentation of further trial data in October and the initiation of the regulatory submission process later this year.

  • Anglo Asian Mining H1 Revenue Rises to $141.2 Million as Copper Production Reaches Record 8,840 Tonnes

    Anglo Asian Mining H1 Revenue Rises to $141.2 Million as Copper Production Reaches Record 8,840 Tonnes

    Anglo Asian Mining PLC (LSE:AAZ) reported revenue of $141.2 million for the six months ended 30 June 2026, compared with $40.9 million a year earlier, as copper production reached a record half-year level of 8,840 tonnes.

    The Azerbaijan-focused copper, gold and silver producer reported profit before tax of $68.5 million and operating cash flow of $78.5 million. Its net cash position increased to $57.7 million at the period-end.

    Following the results, the board declared an interim dividend of six US cents per share.

    The increase in revenue was supported by higher copper production, increased silver output and higher market metal prices. Copper has become the company’s principal product as it expands its production portfolio.

    During the first half, Anglo Asian continued ramping up operations at the Demirli mine, which is expected to reach steady-state production in the fourth quarter of 2026.

    The company also progressed production at Gilar and expanded its processing infrastructure at Gedabek.

    Infrastructure developments included the commissioning of nine new Imhoflot flotation cells, completion of a tailings dam raise at Gedabek and construction of a private haul road connecting Gilar with the processing facilities.

    The new road is intended to increase ore transportation capacity between the mine and processing plants.

    Anglo Asian maintained its full-year production guidance for copper and silver but reduced its gold output forecast following lower-than-expected recoveries from ore mined at Gilar.

    The company also lowered its all-in sustaining cost guidance for copper production, citing operational efficiencies and higher market metal prices. Revenue is currently running ahead of budget, according to management.

    Alongside its existing operations, Anglo Asian is advancing feasibility studies for the Xarxar and Garadag copper projects.

    The company appointed Worley Europe as a consultant for the studies, while internal technical work includes mineralogical assessments and pilot facilities for heap leaching and solvent extraction-electrowinning (SX/EW) processing.

    Anglo Asian is targeting production from Xarxar and Garadag in 2028 and 2029, respectively, as part of its broader development programme.

    Its strategy also includes the Zafar project, with the company planning to bring additional assets into production between 2027 and 2030.

    The group aims to become a multi-asset, mid-tier copper-focused producer by 2030, targeting annual copper production of approximately 50,000 to 55,000 tonnes.

    Exploration activities are continuing alongside the development programme, including drilling intended to support resource evaluation and future mine planning.

    In environmental and social management, Anglo Asian is implementing an integrated Environmental and Social Management System and introducing new environmental standards across the group.

    The company has received an initial Digbee ESG rating and has committed to adopting the Global Industry Standard on Tailings Management by the end of 2026.

    It also plans to develop a biodiversity management standard as part of its environmental management programme.

    Anglo Asian’s near-term operational priorities include completing the production ramp-up at Demirli, progressing feasibility work at Xarxar and Garadag, and implementing its revised production and cost guidance for the remainder of 2026.

  • Iofina H1 Revenue Rises 7% to $31.3 Million as Adjusted EBITDA More Than Doubles

    Iofina H1 Revenue Rises 7% to $31.3 Million as Adjusted EBITDA More Than Doubles

    Iofina plc (LSE:IOF) reported a 7% increase in revenue to a record $31.3 million for the first half of 2026, with adjusted EBITDA more than doubling to $6.6 million as iodine production increased and cost of sales declined.

    The iodine producer and specialty chemicals manufacturer reported an 8% reduction in cost of sales, contributing to a 62% increase in gross profit to $10.2 million.

    Operating profit rose 178% to $4.9 million, while the group reported a net cash position of $7.2 million at the period-end.

    Iofina produced 393.3 metric tonnes of crystalline iodine during the six months, representing a 29% increase year on year and exceeding its revised production target.

    The company said iodine prices remained firm during the period, while increased sales of crystalline iodine and iodine derivatives contributed to its financial performance.

    Capital expenditure totalled $5.8 million in the first half as Iofina continued investing in additional production capacity.

    The expansion programme includes IO#12, the company’s largest iodine extraction plant, located in the Permian Basin, alongside the development of IO#13 and IO#14 in central Oklahoma.

    Management is directing operating cash flow towards these projects as part of its strategy to increase iodine production.

    Iofina is targeting record annual iodine output in 2026 and continues to pursue its longer-term objective of reaching 2,000 metric tonnes of annual production capacity.

    The company currently operates eight IOsorb iodine extraction plants in Oklahoma and describes itself as the second-largest iodine producer in North America.

    Its operations use proprietary WET IOsorb technology to recover iodine from brine produced during oil and gas extraction in the United States.

    The group operates through Iofina Resources, which focuses on iodine extraction, and Iofina Chemical, which manufactures iodine derivatives and other specialty chemicals.

    Iofina’s immediate priorities include progressing construction of its additional extraction plants and increasing production as it works towards its annual output and longer-term capacity targets.

  • Craneware Reports FY26 Revenue of $206 Million and Revises FY27 Outlook Following Cyber Incident

    Craneware Reports FY26 Revenue of $206 Million and Revises FY27 Outlook Following Cyber Incident

    Craneware plc (LSE:CRW) reported broadly unchanged revenue of $206 million for the 2026 financial year, with adjusted EBITDA increasing 3%, as the healthcare software provider revised its revenue expectations for FY27 following a post-year-end cybersecurity incident and ongoing challenges in the US 340B market.

    Annual recurring revenue (ARR) remained stable at $185 million, supported by customer retention and recurring software subscriptions. The company also reported high operating cash conversion during the year.

    Craneware maintained its dividend and completed a $25 million share buyback during the period.

    The group continued developing its Trisus cloud platform, integrating its datasets and expanding the deployment of Trisus Assist, an artificial intelligence-powered tool designed to support financial analysis and decision-making across multiple product areas.

    Craneware also introduced Trisus OneLink – Medication, a product developed to address changes in the US 340B drug pricing programme and pharmacy reimbursement arrangements.

    The company expanded its relationship with Microsoft and secured additional contracts through the Azure Marketplace.

    Following the financial year-end, Craneware identified a cybersecurity incident. The company said the incident did not disrupt customer services or its core operations.

    An independent investigation subsequently confirmed that its systems were secure and fully operational, according to the company. Remediation activities and regulatory reporting remain ongoing.

    In response to the incident and current trading conditions, Craneware’s board has revised its FY27 revenue expectations to align with existing ARR levels of approximately $185 million.

    The revised outlook also reflects the continuing impact of conditions in the 340B market, which have constrained revenue.

    Management has initiated a comprehensive review of the group’s cost base, with the objective of maintaining adjusted EBITDA margins while supporting ongoing product development and commercial activities.

    Craneware expects conditions in the 340B market to become more supportive during the second half of FY27, potentially increasing demand for its software and services. However, the company has not included any anticipated improvement in its current forecasts.

    The group is targeting a return to revenue growth in FY28 and subsequent financial years, supported by its existing customer relationships, recurring revenue base and recently introduced products.

    Craneware provides financial performance and operational software to healthcare organisations in the United States. Its Trisus platform combines healthcare data, revenue management, margin analysis and other financial tools.

    The company’s product portfolio includes software and services addressing hospital reimbursement, charge capture, pharmacy operations and the 340B drug pricing programme.

    Its immediate priorities include completing the remaining cybersecurity remediation and reporting work, reviewing operating costs and implementing its revised FY27 financial plan.